Your fact-checks will appear here
The co-infection of Loa-loa and its relation to ivermectin treatment
Randomized and non-randomized clinical trials have tested ivermectin across a range of doses and disease severities for COVID-19; most peer‑reviewed randomized controlled trials (RCTs) and several met...
High‑dose or prolonged ivermectin use has most often produced mild, transient symptoms—headache, dizziness, nausea, rash and gastrointestinal upset—across clinical studies, but rare serious events inc...
Ivermectin is an effective, evidence-based antiparasitic for specific human infections — notably onchocerciasis and strongyloidiasis — when used at approved doses under medical supervision . It is not...
Repeating ivermectin is routine for onchocerciasis (often yearly) and sometimes necessary for strongyloidiasis—especially in immunocompromised patients—but repetition brings predictable risks that can...
Loa loa co‑infection raises the risk of encephalopathy after ivermectin principally when patients harbour very high peripheral microfilarial densities; rapid killing or redistribution of those microfi...
Ivermectin’s most common adverse reactions in humans are generally mild and gastrointestinal or neurocognitive in nature—nausea, diarrhea, dizziness, and drowsiness—while allergic and dermatologic rea...